Does the media refer more to KYMR or AGIO?

In the previous week, Kymera Therapeutics had 17 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 23 mentions for Kymera Therapeutics and 6 mentions for Agios Pharmaceuticals. Kymera Therapeutics' average media sentiment score of 0.38 beat Agios Pharmaceuticals' score of 0.01 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 10 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AGIO or TGTX?

In the previous week, Agios Pharmaceuticals had 5 more articles in the media than TG Therapeutics. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.72 beat Agios Pharmaceuticals' score of 0.01 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer APGE or AGIO?

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Apogee Therapeutics. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.18 beat Agios Pharmaceuticals' score of 0.01 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AGIO or PCVX?

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Vaxcyte. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.61 beat Agios Pharmaceuticals' score of 0.01 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Agios Pharmaceuticals (AGIO) Competitors

$37.58 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$37.58 +0.01 (+0.01%)

As of 07/2/2026 04:40 PM Eastern

Compare

AGIO vs. KYMR, TGTX, APGE, PCVX, and QGEN

Should you buy Agios Pharmaceuticals stock or one of its competitors? MarketBeat compares Agios Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Agios Pharmaceuticals include Kymera Therapeutics (KYMR), TG Therapeutics (TGTX), Apogee Therapeutics (APGE), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

How does Agios Pharmaceuticals compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Kymera Therapeutics has a net margin of -611.94% compared to Agios Pharmaceuticals' net margin of -639.84%. Kymera Therapeutics' return on equity of -24.71% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Kymera Therapeutics currently has a consensus target price of $121.41, indicating a potential upside of 6.96%. Agios Pharmaceuticals has a consensus target price of $40.89, indicating a potential upside of 8.80%. Given Agios Pharmaceuticals' higher possible upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Kymera Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	238.14	-$311.35M	-$3.57	N/A
Agios Pharmaceuticals	$54.03M	41.36	-$412.78M	-$7.25	N/A

In the previous week, Kymera Therapeutics had 17 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 23 mentions for Kymera Therapeutics and 6 mentions for Agios Pharmaceuticals. Kymera Therapeutics' average media sentiment score of 0.38 beat Agios Pharmaceuticals' score of 0.01 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	10 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Summary

Kymera Therapeutics beats Agios Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to TG Therapeutics?

Agios Pharmaceuticals (NASDAQ:AGIO) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

TG Therapeutics has a net margin of 65.95% compared to Agios Pharmaceuticals' net margin of -639.84%. TG Therapeutics' return on equity of 88.73% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
TG Therapeutics	65.95%	88.73%	43.44%

Agios Pharmaceuticals presently has a consensus target price of $40.89, indicating a potential upside of 8.80%. TG Therapeutics has a consensus target price of $58.60, indicating a potential upside of 9.92%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

58.6% of TG Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Agios Pharmaceuticals had 5 more articles in the media than TG Therapeutics. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.72 beat Agios Pharmaceuticals' score of 0.01 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	41.36	-$412.78M	-$7.25	N/A
TG Therapeutics	$616.29M	13.24	$447.18M	$2.86	18.64

Summary

TG Therapeutics beats Agios Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Apogee Therapeutics presently has a consensus price target of $121.25, suggesting a potential downside of 8.77%. Agios Pharmaceuticals has a consensus price target of $40.89, suggesting a potential upside of 8.80%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

79.0% of Apogee Therapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Apogee Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Apogee Therapeutics' return on equity of -32.64% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Apogee Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Apogee Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Agios Pharmaceuticals	$54.03M	41.36	-$412.78M	-$7.25	N/A

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Apogee Therapeutics. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.18 beat Agios Pharmaceuticals' score of 0.01 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Apogee Therapeutics beats Agios Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Vaxcyte?

Agios Pharmaceuticals (NASDAQ:AGIO) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Vaxcyte has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Vaxcyte's return on equity of -32.51% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Vaxcyte	N/A	-32.51%	-29.51%

Agios Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	41.36	-$412.78M	-$7.25	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Agios Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Agios Pharmaceuticals currently has a consensus target price of $40.89, suggesting a potential upside of 8.80%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 47.29%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Vaxcyte. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.61 beat Agios Pharmaceuticals' score of 0.01 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.8% of Vaxcyte shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Vaxcyte beats Agios Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Qiagen?

Qiagen (NYSE:QGEN) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Qiagen has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.95	$424.88M	$1.91	20.98
Agios Pharmaceuticals	$54.03M	41.36	-$412.78M	-$7.25	N/A

Qiagen has a net margin of 19.16% compared to Agios Pharmaceuticals' net margin of -639.84%. Qiagen's return on equity of 14.40% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Qiagen currently has a consensus price target of $43.15, indicating a potential upside of 7.65%. Agios Pharmaceuticals has a consensus price target of $40.89, indicating a potential upside of 8.80%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Agios Pharmaceuticals had 6 more articles in the media than Qiagen. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 0 mentions for Qiagen. Agios Pharmaceuticals' average media sentiment score of 0.01 beat Qiagen's score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Qiagen	Neutral
Agios Pharmaceuticals	Neutral

Summary

Qiagen beats Agios Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Agios Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGIO vs. The Competition

Export

Metric	Agios Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.23B	$3.76B	$7.16B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.51%
P/E Ratio	-5.18	21.80	27.78	24.70
Price / Sales	41.36	324.78	580.46	116.03
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.84	8.66	10.96	6.46
Net Income	-$412.78M	$23.81M	$3.57B	$337.01M
7 Day Performance	-0.84%	3.39%	2.12%	1.69%
1 Month Performance	30.28%	6.15%	2.80%	0.67%
1 Year Performance	4.23%	62.61%	33.40%	23.93%

Agios Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGIO Agios Pharmaceuticals	1.6639 of 5 stars	$37.58 flat	$40.89 +8.8%	+4.2%	$2.23B	$54.03M	N/A	390	Analyst Revision
KYMR Kymera Therapeutics	1.8168 of 5 stars	$109.32 +1.1%	$120.82 +10.5%	+153.3%	$8.89B	$51.48M	N/A	170	Trending News Analyst Forecast Insider Trade
TGTX TG Therapeutics	3.3511 of 5 stars	$55.72 -0.2%	$58.60 +5.2%	+43.3%	$8.55B	$616.29M	19.48	290
APGE Apogee Therapeutics	1.1299 of 5 stars	$132.61 +0.0%	$121.25 -8.6%	+179.5%	$8.21B	N/A	N/A	91	Insider Trade
PCVX Vaxcyte	2.0235 of 5 stars	$57.72 +2.1%	$86.00 +49.0%	+75.7%	$8.16B	N/A	N/A	160	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGIO) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. KYMR, TGTX, APGE, PCVX, and QGEN

How does Agios Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does Agios Pharmaceuticals compare to TG Therapeutics?

Summary

How does Agios Pharmaceuticals compare to Apogee Therapeutics?

Summary

How does Agios Pharmaceuticals compare to Vaxcyte?

Summary

How does Agios Pharmaceuticals compare to Qiagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. KYMR, TGTX, APGE, PCVX, and QGEN

How does Agios Pharmaceuticals compare to Kymera Therapeutics?

Is KYMR or AGIO more profitable?

Do analysts recommend KYMR or AGIO?

Which has better earnings & valuation, KYMR or AGIO?

Does the media refer more to KYMR or AGIO?

Which has more volatility & risk, KYMR or AGIO?

Summary

How does Agios Pharmaceuticals compare to TG Therapeutics?

Is AGIO or TGTX more profitable?

Do analysts recommend AGIO or TGTX?

Do institutionals & insiders believe in AGIO or TGTX?

Does the media favor AGIO or TGTX?

Which has more risk and volatility, AGIO or TGTX?

Which has better earnings & valuation, AGIO or TGTX?

Summary

How does Agios Pharmaceuticals compare to Apogee Therapeutics?

Do analysts recommend APGE or AGIO?

Do institutionals and insiders hold more shares of APGE or AGIO?

Is APGE or AGIO more profitable?

Which has more volatility and risk, APGE or AGIO?

Which has better earnings & valuation, APGE or AGIO?

Does the media prefer APGE or AGIO?

Summary

How does Agios Pharmaceuticals compare to Vaxcyte?

Is AGIO or PCVX more profitable?

Which has better earnings & valuation, AGIO or PCVX?

Which has more risk and volatility, AGIO or PCVX?

Do analysts rate AGIO or PCVX?

Does the media refer more to AGIO or PCVX?

Do institutionals & insiders have more ownership in AGIO or PCVX?

Summary

How does Agios Pharmaceuticals compare to Qiagen?

Which has preferable earnings & valuation, QGEN or AGIO?

Is QGEN or AGIO more profitable?

Which has more risk & volatility, QGEN or AGIO?

Do analysts recommend QGEN or AGIO?

Do institutionals and insiders believe in QGEN or AGIO?

Does the media refer more to QGEN or AGIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools